Delivery Order SPE2DB20D2002-SPE2DB25FL68X
Award Date 8/20/25
Potential Completion Date 8/21/25
Potential Value $110K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...
- The Defense Logistics Agency awarded a $4,212.40 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 31, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of infection caused by...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B vaccine (20 mcg/0.5 mL syringe) on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $113,419 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 12, 2025, with completion targeted for August 13, 2025. This non-set-aside contract employs firm fixed pricing and represents a direct order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. HEPLISAV-B is a recombinant hepatitis B vaccine utilized by the Department of Defense for immunization programs...
- The U.S. Defense Logistics Agency awarded a delivery order valued at $14,637.70 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price delivery order was issued without a set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention...
- The Defense Logistics Agency awarded a delivery order valued at $8,424.80 to AmerisourceBergen Drug Corp on August 4, 2025, for HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competitively awarded. HEPLISAV-B is a recombinant hepatitis B vaccine commonly procured by...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, non-set-aside contract with a completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, reflecting the Defense Logistics Agency's procurement of...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price delivery order represents a non-competitive set-aside award and is being performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B virus infection in adults 18...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes valued at $4,279.18. This is a firm fixed price delivery order with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.15 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 ml syringes on August 7, 2025, with completion expected by August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for use in adult populations, representing part...